PHP


21. Next generation sequencing for cancer drug development and diagnostics.A. Seth (Toronto, ON, Canada)-(Oct. 8)

22.Transporters as mediators of uptake of chemotherapeutic drugs in target and non- target cells.G. Ciarimboli (Munster, Germany)-(Oct. 10)

23. Metal-based drugs and cancer.P. Collery (Bastia, France)-(Oct. 10)

24. Brain cancer treatment: Epigenetic networks.R. Nano and E. Benericetti (Pavia, Italy)-(Oct. 8)

25. Targeting the tumour microenvironment.I. Witz, Y. Keisari (Israel)-(Oct. 6)

26. Breast Cancer: Pathology and Imaging.N.J. Agnantis (Ioannina, Greece)-(Oct. 7)

27. The sugar code in tumor biology/pathology: Principles and Examples.H.-J. Gabius (München, Germany)-(Oct. 6)

28. Microenviromental heterogenecity of brain tumours: Dynamic topographical changes and adaptation to therapies.G.J. Pilkington (Portsmouth, UK)-(Oct. 7)

29. Alternative and complementary medicine in cancer treatment.S. Pathak (Houston, TX, USA)-(Oct. 6)

30. Natural products in cancer drug development.B. Littlefield (Andover, MA, USA)-(Oct. 9)

31. Hypoxia and Cancer Cell Protection in Cancer Metastasis.G. Rutteman (Utrecht, The Netherlands)

32S. New insights in renal cancer (SIUrO Special Symposium).G. Sica (Italy) and G. Conti (Italy), Oct. 7.

1 2

 

 

TK – a prognostic marker for lymphoma and myeloma.V. BarakJerusalemIsrael

Prognostic biomarkers for melanoma.V. BarakJerusalemIsrael

Translational network for predictive, preventive, personalized and participatory cancer study.D.-T. BauTaichungTaiwan

Cancer prevention by screening and early detection.C.-H. YipPetaling JayaMalaysia

Cancer Prevention by control of infectious agents through immunization and therapy.C.J. ChenTaipeiTaiwan

Antitumour activities of rhenium and selenium combined as a rhenium diselenoether compound.P. ColleryAlgajolaFrance

Cancer gene therapy delivery systems.A.Z. DudekChicago, ILUSA

Oncology drug development from bench to bedside.A.Z. DudekChicago, ILUSA

Targeted therapies for musculoskeletal sarcoma.A. DutourLyonFrance

Overcoming multidrug resistance in human cancer cells by plant-derived compounds.M.J.U. FerreiraLisbonPortugal

Glycobiology of tumor suppressor p16INK44.H.J. GabiusMunichGermany

Immunogenic cell death biomarkers in cancer disease.S. HoldenriederBonnGermany

Histone modifications on circulating nucleosomes as new tools for cancer diagnostics.S. HoldenriederBonnGermany

Cancer genomics in translational research and targeted therapy.S.C. JhanwarNew York, NYUSA

Role of robotic surgery in head and neck cancer.R. KnechtHamburgGermany

Role of the art of multimodal treatment of head and neck cancer.R. KnechtHamburgGermany

Therapeutic potential of antiangiogenesis.S. KumarManchesterUK

Reversal of Multidrug Resistance.J. MolnárSzegedHungary

Thermodynamical aspects of cancer growth and possible perspectives.J. MolnárSzegedHungary

Oral cancer biology and diagnosis – in vivo, in vitro, tissue, serum and salivary analyses.R. NaglerHaifaIsrael

1 2 3 4 46